You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb and 360Dx.
The two firms aim to bring down costs and turnaround time with two newly-launched sequencing tests for respiratory pathogens, RVOP 2 and Explify RPIP.
In a conversation at the Association for Molecular Pathology meeting, the directors touched on topics such as test allocation and staffing and reagent shortages.
The Sydney, Australia-based firm has licensed a single biomarker which it plans to develop into a test for triaging COVID-19 patients.
BioFire has submitted a 39-target test to the US Food and Drug Administration. OpGen also has a test in development.
The firm recently described circumstances in which the fraction of host or donor DNA could be altered, and plans new approaches to data interpretation.
Quidel expects to launch at least four new products over the next year and commented on its overall COVID-19 strategy, as well as R&D plans, M&A possibilities, and other updates.
A recent study showed that a method called affine transformation can be used to increase the number of true positive qPCR samples detected.
The initiative will build up pathogen sequencing capacity through investment from the Gates Foundation, Microsoft, Illumina, and Oxford Nanopore.
With nearly 7 million COVID-19 cases, the country is expanding near-patient strategies historically deployed for tuberculosis testing for SARS-CoV-2 testing.
The agency provided the update on Wednesday in its weekly virtual town hall and on its FAQ page.
An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.
The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.
CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.
In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.